GlassScriptPhysician profile
Rohini J Joshi
NPI 1538190806
$7,792.15
in general payments reported to CMS, 2019-2025
41 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,619 · 2020: $2,149 · 2021: $1,670 · 2022: $52.67 · 2023: $176 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,064.61 | 2019-2021 | |
| Livanova USA, INC. | $1,042.44 | 2019-2022 | |
| Abbvie INC. | $940.46 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $662.95 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $584.17 | 2019-2021 | |
| Allergan, INC. | $376.67 | 2019-2021 | |
| Eisai INC. | $349.64 | 2019-2023 | |
| Lilly USA, LLC | $215.48 | 2019-2021 | |
| Ucb, INC. | $214.61 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $187.76 | 2019-2021 | |
| Amgen INC. | $165.75 | 2019-2021 | |
| Genentech USA, INC. | $163.95 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $133.25 | 2019-2020 | |
| Sk Life Science, INC. | $132.84 | 2020-2023 | |
| Emd Serono, INC. | $126.97 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohini Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.